The only once-daily oral preventive CGRP receptor antagonist1

Turn on quick and continuous migraine preventive power with QULIPTA™

Across a 12-week clinical trial (QULIPTA 60 mg)*:

Month Icon

Significant 54% reduction in mean monthly migraine days vs 33% for placebo1,2

– Similar results were seen in the Phase 2b/3 Dose-finding Study

Reduction Icon

Quick migraine day reductions were observed Day 1 after the first dose, Week 1, and Month 13

Patient Icon

Over 60% of patients cut their migraine days by at least half vs 29% for placebo1

*Data from the Phase 3 ADVANCE trial.

Learn more about THE EFFICACY OF QULIPTA

*Data from the Phase 3 ADVANCE trial.

INDICATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily. 
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily. 
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

Please see full Prescribing Information.

References

QULIPTATM and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.

© 2021 AbbVie. All rights reserved.

ATP145671

Welcome to quliptahcp.com.

This website is intended for US healthcare professionals.

Are you a healthcare professional in the US?

Yes
No

Study Design

Two randomized, double-blind, placebo-controlled, parallel-group studies that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 4 to 14 migraine days per month. Patients in trials were 88% female, 80% White, 17% Black, and 12% Hispanic or Latino ethnicity and the mean age at study entry was 41 years (range 18-74 years).1,2

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily. 
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily. 
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

Please see full Prescribing Information.